9,630
Total Claims
$2.2M
Drug Cost
1,030
Beneficiaries
$2,109
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+38%
Cost per patient vs peers
$2,109 vs $1,524 avg
+60%
Brand preference vs peers
21.8% vs 13.7% avg
Brand vs Generic
78% generic
Brand: 2,095 claims · $2.0M
Generic: 7,524 claims · $156K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 878 | $896K |
| Empagliflozin | 324 | $297K |
| Rivaroxaban | 252 | $262K |
| Sacubitril/Valsartan | 244 | $239K |
| Evolocumab | 116 | $76K |
| Ticagrelor | 42 | $26K |
| Alirocumab | 35 | $18K |
| Evolocumab | 12 | $18K |
| Ezetimibe | 549 | $15K |
| Metoprolol Succinate | 758 | $12K |
| Rosuvastatin Calcium | 486 | $8,415 |
| Nebivolol Hcl | 110 | $8,333 |
| Evolocumab | 14 | $8,213 |
| Icosapent Ethyl | 11 | $7,781 |
| Atorvastatin Calcium | 581 | $7,589 |
Prescribing Profile
70
Unique Drugs
$1.7M
Patient Profile
78
Avg Age
48%
Female
1.47
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data